Vector Science & Therapeutics Corp.PAIN.V

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX-V · United States · vectorscience.co

Vector Science and Therapeutics develops novel biomechanical devices and active localized drug-delivery platforms for site-directed interventions in musculoskeletal tissue regeneration, including transdermal drug delivery. Based in Mequon, Wisconsin, the company listed on the TSX Venture Exchange in April 2026 (formerly OpenSesame Acquisition Corp.) and has a development and manufacturing agreement with MPP Group LLC for pharmaceutical-grade peptides and drug delivery devices.

Key ratios

ROA

-19.0%TTM

2025 -19.0%

ROE

-104.1%TTM

2025 -104.1%

Recent news

Vector Science and Therapeutics Corp. Enters Into an Investor Relations Agreement and Grants Options 2026-08-26 · CNW Vector Science & Therapeutics Begins Peptide Production as First LyoGenesis Suite Comes Online 2026-08-24 · CNW Vector Science and Therapeutics Corp. (TSXV: PAIN) Files Provisional Patent Application on Integrated Platform for Orthopedic Tissue Regeneration Using Peptides 2026-08-20 · CNW Correction: Verlytix Launches as a Related Company to LyoGenesis Manufacturing 2026-08-19 · CNW Vector Science and Therapeutics Signs Amended 10-Year Manufacturing Agreement with LyoGenesis 2026-08-17 · CNW Vector Science & Therapeutics Reports First Quarterly Financial Results as a Public Company; Announces Inaugural Investor Q&A on July 28 2026-07-24 · CNW Vector Science & Therapeutics Announces Distributor Network Buildout to Support Its Peptide Portfolio Across Orthopedic, Sports, and Regenerative Medicine Channels 2026-07-21 · CNW Vector Science & Therapeutics Builds 15-Patent-Application Intellectual Property Portfolio Around Precision Therapeutic Delivery, Anchored by Peptide and Biologic Administration Technologies 2026-07-15 · CNW Vector Science & Therapeutics Announces Landmark Exclusive cGMP Manufacturing Agreement with LyoGenesis Plus for Its Proprietary Peptide Portfolio 2026-07-07 · Newswire (CNW)

Track PAIN.V in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer